Feasibility of MR-guided ultrahypofractionated radiotherapy in 5, 2 or 1 fractions for prostate cancer
Author:
Funder
Rosetrees Trust
Cancer Research UK
Publisher
Elsevier BV
Subject
Radiology Nuclear Medicine and imaging,Oncology
Reference36 articles.
1. Randomized Trial of a Hypofractionated Radiation Regimen for the Treatment of Localized Prostate Cancer;Catton;J Clin Oncol,2017
2. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial;Dearnaley;Lancet Oncol,2016
3. Randomized phase III noninferiority study comparing two radiotherapy fractionation schedules in patients with low-risk prostate cancer;Lee;J Clin Oncol,2016
4. Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trial;Incrocci;Lancet Oncol,2016
5. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial;Widmark;Lancet,2019
Cited by 12 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Beginning of clinical treatment using the 1.5 Tesla MR-Linac system in Japan: a narrative review;Translational Cancer Research;2024-02
2. Real‐time motion‐including dose estimation of simulated multi‐leaf collimator‐tracked magnetic resonance‐guided radiotherapy;Medical Physics;2023-10-28
3. Evaluation of Unity 1.5 T MR‐linac plan quality in patients with prostate cancer;Journal of Applied Clinical Medical Physics;2023-08-10
4. MRI-guided Radiotherapy (MRgRT) for Treatment of Oligometastases: Review of Clinical Applications and Challenges;International Journal of Radiation Oncology*Biology*Physics;2022-12
5. A Prospective Study of Stereotactic Body Radiotherapy (SBRT) with Concomitant Whole-Pelvic Radiotherapy (WPRT) for High-Risk Localized Prostate Cancer Patients Using 1.5 Tesla Magnetic Resonance Guidance: The Preliminary Clinical Outcome;Cancers;2022-07-18
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3